Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor

Seock Ah Im, Sung Bae Kim, Moon Hee Lee, Young Hyuck Im, Kyung Hee Lee, Hong Suk Song, Myung Ah Lee, Junglim Lee, Nam Su Lee, Hae Sun Ham, Tae You Kim, Yeon Hee Park, Kyung Eun Lee, Kee Won Kim, Jae Hong Seo, Soon Nam Lee, Young Seon Hong, Yung Jue Bang, Woo Kun Kim, Hee Sook Park

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor'. Together they form a unique fingerprint.

Medicine & Life Sciences